Histone deacetylase inhibitors are potent radiation protectants

Cancer Biology and Therapy

Volumn 3, Issue 7, 2004, Pages 612-613

  Paoluzzi, Luca ^a,b   Figg, William D ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cutaneous radiation syndrome; Histone deacetylase inhibitors; Phenylbutyrate; Radiotherapy

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; RADIOPROTECTIVE AGENT; TRICHOSTATIN A; VALPROIC ACID; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HISTONE;

CANCER INHIBITION; CANCER RADIOTHERAPY; HUMAN; NONHUMAN; RADIATION INJURY; SHORT SURVEY; SKIN INJURY; SKIN TUMOR; ACETYLATION; ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; NEOPLASM; RADIOTHERAPY; REVIEW;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY;

EID: 16644389497     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.7.931     Document Type: Short Survey

References (15)

1. Figg WD, Walls RG, Cooper MR, Thibault A, Sartor O, McCall NA, et al. In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. Anticancer Drugs 1994; 5:336-42.
2. Boudoulas S, Lush RM, McCall NA, Samid D, Reed E, Figg WD. Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents. Ther Drug Monit. 1996; 18:714-20.
3. Melchior SW, Brown LG, Figg WD, Quinn JE, Santucci RA, Brunner J, et al. Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. Int J Oncol 1999; 14:501-8.
4. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitor: Induction of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92:1210-6.
5. Richon VM, O'Brien JP. Histone deacetylase inhibitors: A new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 2002; 9:662-7.
6. Vigushin DM, Coombes RC. Targeted histone deacetylase inhibition for cancer therapy Curr Cancer Drug Targets 2004; 4:205-18.
7. Grdina DJ, Murley JS, Kataoka Y. Radioprotectants: Current status and new directions. Oncology 2002; 63:2-10.
8. Lee TK, Stupans L. Radioprotection: The nonsteroidal anti-inflammatory drugs (NSAIDs) and prostaglandins. J Pharm Pharmacol 2002; 54:1435-45.
9. Chung YL, Wang AJ, Yao LF. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. Mol Cancer Ther 2004; 3:317-25.
10. Zhou D, Yu T, Chen G, Brown SA, Yu Z, Mattson MP, et al. Effects of NF-kappaB1 (p50) targeted gene disruption on ionizing radiation-induced NF-kappa B activation and TNFα, IL-1α, IL-1β and IL-6 mRNA expression in vivo. Int J Radiat Biol Jul 2001; 77:763-72.
11. Sivan V, Vozenin-Brotons MC, Tricaud Y, Lefaix JL, Cosset JM, Dubray B, et al. Altered proliferation and differentiation of human epidermis in cases of skin fibrosis after radiotherapy. Int J Radiat Oncol Biol Phys Jun 1 2002; 53:385-93.
12. Gilbert J, Baker SD, Bowling MK Grochow L, Figg WD, Zabelina Y, et al. A phase I dose escalation and biovailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001; 7:2292-300.
13. Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, et al. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 2001; 7:3047-55.
14. Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res Aug 2001; 7:2330-9.
15. Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res Apr 2002; 8:963-70.